Lakewood-Amedex Biotherapeutics, Inc.
LABTRating Trend
Earnings History
Next report: Nov 12, 2026 · EPS est. $-1.33| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 13, 2026 | $-2.75 | $-2.66 | — | — |
| May 22, 2026 | $-1.32 | — | — | — |
News
SARASOTA, Fla., Nov. 5, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc.
Research highlights Nu-3's rapid bactericidal activity against clinically relevant resistant pathogens and its potential as a topical treatment for infected diabetic foot ulcers SARASOTA, Fla., Oct. 21, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT, the "Company"), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class, today announced the presentation …
Lakewood-Amedex Biotherapeutics Inc. (NASDAQ: LABT - Get Free Report) was the recipient of a significant increase in short interest in the month of September. As of September 30th, there was short interest totaling 130,722 shares, an increase of 146.8% from the September 15th total of 52,967 shares. Currently, 5.8% of the shares of the company are
Intravesical administration of the Bisphosphocin ® Nu-8 to rodents infected with E. coli demonstrated up to 97% inhibition of E.
SARASOTA, Fla., Oct. 1, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics, Inc. (NASDAQ: LABT, the "Company"), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class, today announced that CEO Kelvin Cooper, Ph.D.
Lead candidate Nu-3 is a topically formulated Bisphosphocin ® , designed to rapidly kill microbes while reducing the risk of antimicrobial resistance SARASOTA, Fla., Sept. 28, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT, the "Company"), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class, announced positive Minimum Inhibitory Concentration (MIC) da…
Initiation of patient dosing marks significant clinical development milestone for Nu-3 and Lakewood-Amedex Biotherapeutics' proprietary Bisphosphocin ® antimicrobial platform Topline data expected in the first quarter of 2027 SARASOTA, Fla., Sept. 24, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT, the "Company"), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bispho…
Clinical and Corporate Highlights Successfully listed on the Nasdaq Capital Market under the ticker symbol LABT, marking a significant milestone in the Company's evolution Strengthened balance sheet through completion of a $7.5 million private placement to support continued clinical advancement Reported positive preclinical safety and tolerability data supporting dose selection for the upcoming Phase 2a clinical trial evaluating Nu-3 Gel in infected diabetic foot ulcers (iDFUs) Announced interna…
SARASOTA, Fla., Sept. 18, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT, the "Company"), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class, today announced that it has obtained central and all site Institutional Review Board (IRB) approvals and confirmed clinical trial site readiness to commence its Phase 2a clinical trial evaluating the safety and…
SARASOTA, Fla., Sept. 8, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT, the "Company"), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class, today announced that Kelvin Cooper, Ph.D.